Evaluation of less treatment interruption of 6-Mercaptopurine by co-administration of ursodeoxycholic acid with chemotherapy in pediatric acute lymphoblastic leukemia

Nafisa Yesmin; M. Anwarul Karim; Abu Haider Mohammad Raziul Mazid; Niaz Mahmud

doi:10.18203/2349-3291.ijcp20241029

Authors

Nafisa Yesmin Department of Pediatric Hematology and Oncology, Rangpur Medical College and Hospital, Rangpur, Bangladesh
M. Anwarul Karim Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Abu Haider Mohammad Raziul Mazid Gaibandha General Hospital, Gaibandha, Bangladesh
Niaz Mahmud Department of Pediatric Hematology and Oncology, Sher-E-Bangla Medical College and Hospital, Barishal, Bangladesh

DOI:

https://doi.org/10.18203/2349-3291.ijcp20241029

Keywords:

Ursodeoxycholic acid, Chemotherapy, Pediatric hematology and oncology

Abstract

Background: Ursodeoxycholic acid (UDCA), a bile acid, protects the liver through various mechanisms, including bile composition modulation and enhanced secretion. In ALL chemotherapy, 6MP is hepatotoxic, requiring dose reduction. UDCA is used to alleviate liver toxicity in ALL and other chronic cholestatic conditions. The study aims to evaluate the effectiveness of UDCA with chemotherapy in reducing 6MP treatment interruptions and its impact on treatment continuity in pediatric ALL.

Methods: This randomized controlled trial study conducted at the Department of Pediatric Hematology and Oncology, BSMMU in pediatric ALL patients during chemotherapy from September 2018 to August 2019. Fifty children aged 1 to 18 years with ALL were enrolled, half receiving UDCA alongside chemotherapy and the rest forming the control group. Serum hepatic transaminases, total bilirubin, and CBC were monitored every 14 days. Statistical analysis was performed using SPSS, with significance set at p<0.05.

Results: In this study of 50 pediatric ALL patients, there were no statistically significant age or gender differences between the "Case" (UDCA-treated) and "Control" groups. However, the UDCA group showed a significant decrease in abnormal liver function tests (32.0%) compared to controls (60.0%). Moreover, 6MP dose reduction was significantly lower in cases (4.0%) than controls (40.0%), indicating UDCA's potential hepatoprotective effects. Multivariate logistic regression revealed male gender and mean AST levels as significant factors associated with hepatotoxicity in pediatric ALL patients.

Conclusions: Co-administration of UDCA with chemotherapy demonstrates a significant effect in treatment interruption by hepatotoxic drug specially 6 MP in pediatric ALL patients.

Metrics

Metrics Loading ...

References

Yamazaki K, Suzuki K, Nakamura A, Sato S, Lindor KD, Batts KP, Tarara JE, Kephart GM, Kita H, Gleich GJ. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology. 1999;30(1):71-8.

Bhojwani D, Yang JJ, Pui CH. Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):47-60.

Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33(1):50-67.

Topley JM, Benson J, Squier MV, Chessells JM. Hepatotoxicity in the treatment of acute lymphoblastic leukaemia. Med Pediatr Oncol. 1979; 7(4):393-9.

Grigorian A, O'Brien CB. Hepatotoxicity Secondary to Chemotherapy. J Clin Transl Hepatol. 2014;2(2): 95-102.

Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15(4): 1560-6.

Mohammed Saif M, Farid SF, Khaleel SA, Sabry NA, El-Sayed MH. Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2012;29(7):627-32.

Barrington-Trimis JL, Cockburn M, Metayer C, Gauderman WJ, Wiemels J, McKean-Cowdin R. Rising rates of acute lymphoblastic leukemia in Hispanic children: trends in incidence from 1992 to 2011. Blood. 2015;125(19):3033-4.

Lustosa de Sousa DW, de Almeida Ferreira FV, Cavalcante Félix FH, de Oliveira Lopes MV. Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015;37(4):223-9.

Konstantinos N, Gregory L, Gores J, Keith D. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol. 2021;35:131-46.

Rashidy HF, Ragab MS, Dawood AA, Temraz SA. Toxic complications of treatment with 6-mercaptopurine in pediatric acute lymphoblastic leukemia. Menoufia Med J. 2019;28:411-4.

Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterol. 2005;129(2):512-21.

Barrington-Trimis JL, Cockburn M, Metayer C, Gauderman WJ, Wiemels J, McKean-Cowdin R. Rising rates of acute lymphoblastic leukemia in Hispanic children: trends in incidence from 1992 to 2011. Blood. 2015;125(19):3033-4.

Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78.

Schmiegelow K, Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer. 1990;61(5):767-72.

Stoneham A. Acute Leukemia- The Scientist’s Perspective and Challenge. 4th ed. Croatia: InTech; 2003:3;211-9.